Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

New CAPLYTAо (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATOо (esketamine) effects on anhedonia in treatment-resistant depression (TRD) Ц Phase 3 data post-hoc analyses to be presented Comparative tolerability of adjunctive seltorexant vs. adjunctive quetiapine XR in major depressive disorder (MDD) with insomnia symptoms Ц new Phase 3 metabolic analyses will also be presented TITUSVILLE, N.J., Jan. 13, 2026 /P ...